Ojasimmune develops platform technologies that reprogram innate immune cells, focusing on macrophages through synthetic biology, stem‑cell methods, genome engineering, and computational modeling. By leveraging a knowledge‑driven, cross‑disciplinary approach, the company creates engineered macrophage therapies aimed at unlocking the immune system’s therapeutic potential across a broad range of diseases. Their platforms integrate genome‑edited cells with predictive modeling to accelerate the design and production of next‑generation immunotherapies.
Funding
Funding not disclosed
Founders
Product
Problem
Current immunotherapies largely target adaptive immune cells and often rely on broad, systemic modulation, which can lead to off‑target effects and limited efficacy for many diseases. The innate immune system, particularly macrophages, remains underexploited despite its central role in tissue homeostasis, inflammation, and disease resolution.
Solution
Ojasimmune develops a platform that reprograms macrophages using synthetic biology, stem‑cell techniques, genome engineering, and computational modeling. By integrating deep biological insight with engineering tools, the platform enables rational design of engineered macrophage cells tailored to specific therapeutic goals. These engineered cells can be produced at scale and programmed to perform defined functions such as targeted inflammation resolution, tissue repair, or anti‑tumor activity. The approach aims to expand the therapeutic repertoire of the innate immune system across a wide spectrum of indications, offering more precise and customizable immune interventions.
Target Audience
Primary customers are biopharmaceutical companies and research institutions seeking to develop cell‑based immunotherapies that leverage engineered innate immune cells for oncology, inflammatory, and regenerative medicine applications.
Features
- Synthetic biology circuits that endow macrophages with programmable sensing and response capabilities
- Genome‑editing pipelines for precise insertion of therapeutic genes and regulatory elements
- Stem‑cell‑derived macrophage manufacturing process ensuring scalable, GMP‑compatible cell production
- Computational modeling framework to predict cell behavior and optimize design before wet‑lab implementation
- Modular platform architecture allowing rapid adaptation of engineered macrophages to different disease targets